A 64-year-old man with type 2 diabetes and established coronary artery disease has been on maximally tolerated metformin and an ACE inhibitor. His HbA1c remains 63 mmol/mol (7.9%) and he has an eGFR of 58 mL/min/1.73 m² with moderately increased albuminuria. According to contemporary guidelines on diabetes and chronic kidney disease, which additional glucose-lowering therapy is preferred to improve both renal and cardiovascular outcomes?